Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 2009

View Archived Issues

Aflunov vaccine immunogenic and well tolerated in children and adolescents

FDA approves Roche's test to screen source plasma for HIV, HBV and HCV

Phase I trial reveals promising activity of MGCD-265 in advanced malignancies

NMS-P-715 inhibits tumor growth by targeting the mitotic checkpoint

Astellas reports results from first half of 2009, ended September 30

Shionogi reports results from Q2 of 2009, ended September 30

AstraZeneca and Targacept collaborate on TC-5214 for major depressive disorder

Cosmo Technologies completes enrollment in phase III budesonide MMX trial

Cubist closes enrollment early in CONSERV-1 and CONSERV-2

Novavax reports promising results from pandemic influenza vaccine trial

FDA approves Novo Nordisk's Vagifem 10 mcg for atrophic vaginitis due to menopause

Peregrine completes enrollment in dose confirmation trial of Cotara in brain cancer

Via Pharmaceuticals completes patient visits in phase II VIA-2291 trial

Tripep receives approval to expand ChronVac-C study

API-101.10 protects against hyperoxia-induced retinopathy in vivo

Antithrombotic nanobody ALX-0681 safe and well tolerated in healthy volunteers

Safety of MLN-4924 in MM and NHL shown in preliminary data from phase I trial

CK2 inhibitors for the treatment of cancer in development at Cylene Pharmaceuticals

Auckland UniServices claims PI3K p110alpha inhibitors for cancer therapy

Novel prostanoid EP2 agonists disclosed by Ube for asthma therapy

Forest identifies novel SCD1 inhibitors for the treatment of obesity

German scientists describe novel ClpP inhibitors as antibacterial agents

Amira presents initial phase I data for AM-461

Chaperone Technologies and MerLion collaborate on antimicrobials

FDA approves Lilly's Zyprexa tablets for psychiatric disorders in adolescents

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...